[Hemorheologic therapy in peripheral arterial occlusive disease].
In view of current knowledge drug treatment of peripheral arterial occlusive disease is required at stage IIb in most cases. Angiological diagnostic procedures should be conducted to determine the location and extent of occlusion as well as to evaluate the blood fluidity. Rheological therapy is indicated in cases of microangiopathy, inoperable macroangiopathy, pre- and postoperative treatment of macroangiopathy and macroangiopathy after angioplasty or fibrinolysis. Drug treatment is administered according to clinical status and rheological parameters. The main emphasis in therapy includes hemodilution, reducing the fibrinogen concentration and improvement of blood fluidity. The findings of hemodilution therapy with various hydroxy-ethyl starches as well as a monotherapy with naftidrofuryl are presented and discussed.
D000328:Adult; D000368:Aged; D001157:Arterial Occlusive Diseases / Q000628:therapy*; D003131:Combined Modality Therapy; D006400:Hematocrit; D006438:Hemodilution / Q000379:methods*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D007866:Leg / Q000098:blood supply; D008875:Middle Aged; D009257:Nafronyl / Q000627:therapeutic use; D012212:Rheology; D012306:Risk; D013927:Thrombosis / Q000628:therapy*
D009257:Nafronyl
Hämorheologische Therapie bei peripherer arterieller Verschlusskrankheit.